|
1
|
Im NR, Yang TD, Park K, Lee JH, Lee J, Hyuck Kim Y, Lee JS, Kim B, Jung KY, Choi Y, Baek SK. Application of M1 macrophage as a live vector in delivering nanoparticles for in vivo photothermal treatment. J Adv Res 2021; 31:155-163. [PMID: 34194839 PMCID: PMC8240114 DOI: 10.1016/j.jare.2021.01.010] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2020] [Revised: 01/14/2021] [Accepted: 01/19/2021] [Indexed: 11/05/2022] Open
Abstract
Introduction To enhance photothermal treatment (PTT) efficiency, a delivery method that uses cell vector for nanoparticles (NPs) delivery has drawn attention and studied widely in recent years. Objectives In this study, we demonstrated the feasibility of M1 activated macrophage as a live vector for delivering NPs and investigated the effect of NPs loaded M1 stimulated by Lipopolysaccharide on PTT efficiency in vivo. Methods M1 was used as a live vector for delivering NPs and further to investigate the effect of NPs loaded M1 on PTT efficiency. Non-activated macrophage (MФ) was stimulated by lipopolysaccharide (LPS) into M1 and assessed for tumor cell phagocytic capacity towards NPs Results We found M1 exhibited a 20-fold higher uptake capacity of NPs per cell volume and 2.9-fold more active infiltration into the tumor site, compared with non-activated macrophage MФ. We injected M1 cells peritumorally and observed that these cells penetrated into the tumor mass within 12 h. Then, we conducted PTT using irradiation of a near-infrared laser for 1 min at 1 W/cm2. As a result, we confirmed that using M1 as an active live vector led to a more rapid reduction in tumor size within 1 day indicating that the efficacy of PTT with NPs-loaded M1 is higher than that with NPs-loaded MФ. Conclusion Our study demonstrated the potential role of M1 as a live vector for enhancing the feasibility of PTT in cancer treatment.
Collapse
Affiliation(s)
- Nu-Ri Im
- Department of Otolaryngology-Head and Neck Surgery, Korea University, Seoul 02841, South Korea
| | - Taeseok Daniel Yang
- Department of Biomedical Engineering, Brown University, Providence, RI 02912, USA.,School of Biomedical Engineering, Korea University, Seoul 02841, South Korea
| | - Kwanjun Park
- Department of Bioengineering, Korea University, Seoul 02841, South Korea
| | - Jang-Hoon Lee
- Department of Biomedical Engineering, Brown University, Providence, RI 02912, USA
| | - Jonghwan Lee
- Department of Biomedical Engineering, Brown University, Providence, RI 02912, USA
| | - Yoon Hyuck Kim
- Department of Materials Science and Engineering, Korea University, Seoul 02841, South Korea
| | - Jae-Seung Lee
- Department of Materials Science and Engineering, Korea University, Seoul 02841, South Korea
| | - Byoungjae Kim
- Department of Otolaryngology-Head and Neck Surgery, Korea University, Seoul 02841, South Korea.,Department of Neuroscience Research Institute, Korea University, Seoul 02841, South Korea
| | - Kwang-Yoon Jung
- Department of Otolaryngology-Head and Neck Surgery, Korea University, Seoul 02841, South Korea
| | - Youngwoon Choi
- School of Biomedical Engineering, Korea University, Seoul 02841, South Korea.,Department of Bioengineering, Korea University, Seoul 02841, South Korea.,Interdisciplinary Program in Precision Public Health, Korea University, Seoul 02841, South Korea
| | - Seung-Kuk Baek
- Department of Otolaryngology-Head and Neck Surgery, Korea University, Seoul 02841, South Korea
| |
Collapse
|
|
2
|
Abstract
Cancer gene therapy has been one of the most exciting areas of therapeutic research in the past decade. In this review, we discuss strategies to restrict transcription of transgenes to tumour cells. A range of promoters which are tissue-specific, tumour-specific, or inducible by exogenous agents are presented. Transcriptional targeting should prevent normal tissue toxicities associated with other cancer treatments, such as radiation and chemotherapy. In addition, the specificity of these strategies should provide improved targeting of metastatic tumours following systemic gene delivery. Rapid progress in the ability to specifically control transgenes will allow systemic gene delivery for cancer therapy to become a real possibility in the near future.
Collapse
Affiliation(s)
- Tracy Robson
- School of Biomedical Sciences, University of Ulster, Newtownabbey, Co. Antrim, BT37 0QB, Northern Ireland, UK
| | - David G. Hirst
- School of Biomedical Sciences, University of Ulster, Newtownabbey, Co. Antrim, BT37 0QB, Northern Ireland, UK
| |
Collapse
|